FITC anti-mouse CD3 Antibody

Pricing & Availability
Clone
17A2 (See other available formats)
Regulatory Status
RUO
Other Names
T cell antigen receptor complex, T3
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
17A2
C57BL/6 splenocytes stained with 17A2 FITC and 145-2C11 PE
  • 17A2
    C57BL/6 splenocytes stained with 17A2 FITC and 145-2C11 PE
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
100203 50 µg 29€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100204 500 µg 115€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD3, also known as T3, is a member of the Ig superfamily and primarily expressed on T cells, NK-T cells, and at different levels on thymocytes during T cell differentiation. CD3 is composed of CD3ε, δ, γ and ζ chains. It forms a TCR complex by associating with TCR α/β or γ/δ chains. CD3 plays a critical role in TCR signal transduction, T cell activation, and antigen recognition by binding the peptide/MHC antigen complex

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
γδTCR-positive T-T hybridoma D1
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Additional reported application (for relevant formats) include: spatial biology (IBEX)1,2.

Application References

(PubMed link indicates BioLegend citation)
  1. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  2. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Harsha Krovi S, et al. 2020. Nat Commun. 4.790277778. PubMed
  2. Dai L, et al. 2020. Cell. 182(3):722-733.e11. PubMed
  3. Xing J, et al. 2021. Cell Reports. 35(12):109205. PubMed
  4. Zaman R, et al. 2021. Immunity. :. PubMed
  5. Yu X, et al. 2020. Nat Commun. 11:1110. PubMed
  6. Jiang W, et al. 2017. Sci Rep. 7:6501. PubMed
  7. Petrova T, et al. 2020. Sci Rep. 10:3479. PubMed
  8. Zhang H, et al. 2021. Front Immunol. 12:644520. PubMed
  9. Garo LP, et al. 2021. Nat Commun. 12:2419. PubMed
  10. Lee JH, et al. 2022. EBioMedicine. 77:103903. PubMed
  11. Zhu Y, et al. 2022. Nat Commun. 13:4282. PubMed
  12. Bruggemann TR, et al. 2022. iScience. 25:105185. PubMed
  13. Miller CM, et al. 2020. J Virol. 94:00:00. PubMed
  14. Boyd DF, et al. 2020. Nature. 587:466. PubMed
  15. Wu X, et al. 2012. Biochem Pharmacol. 84:1164. PubMed
  16. Lin W, et al. 2020. Theranostics. 10:4871. PubMed
  17. Gawish R, et al. 2022. Elife. 11:. PubMed
  18. Qiao Y, et al. 2021. Oncoimmunology. 10:1947569. PubMed
  19. Li Q, et al. 2022. Cell Rep. 40:111308. PubMed
  20. Manukian G, et al. 2021. Int J Radiat Oncol Biol Phys. 110:1341. PubMed
  21. Jiang Q, et al. 2022. Theranostics. 12:59. PubMed
  22. Wilhelm J, et al. 2021. J Control Release. 329:353. PubMed
  23. Ford K, et al. 2020. Cancer Res. 80:1846. PubMed
  24. Delvecchio FR, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:1543. PubMed
  25. Zhang R, et al. 2021. Cell Mol Immunol. 18:1222. PubMed
  26. Tang L, et al. 2021. Oncol Lett. 22:605. PubMed
  27. Kim D, et al. 2021. Nanomicro Lett. 13:31. PubMed
  28. Bao H, et al. 2020. Mol Med Rep. 4.675. PubMed
  29. Du Q, et al. 2019. Front Microbiol. 10:2050. PubMed
  30. Song C, et al. 2019. Nat Commun. 10:3745. PubMed
  31. Liu QZ, et al. 2018. Front Immunol. 1.131944444. PubMed
  32. Chou YJ, et al. 2020. Sci Rep. 10:8422. PubMed
  33. Bromley SK, et al. 2020. Cell Reports. 32(9):108085. PubMed
  34. Turner JA, et al. 2020. Immunity. 53:1202. PubMed
  35. Jiang W, et al. 2021. Oncol Lett. 22:625. PubMed
  36. Choi YY, et al. 2021. Cell Death Dis. 12:826. PubMed
  37. Almeida AS, et al. 2021. Bio Protoc. 11:e4012. PubMed
  38. Zhang S, et al. 2022. Acta Pharm Sin B. 12:3124. PubMed
  39. Steubing RD, et al. 2022. Brain Behav Immun Health. 24:100493. PubMed
  40. Mei S, et al. 2022. Front Immunol. 13:911164. PubMed
  41. Lu H, et al. 2021. Autophagy. 17:2511. PubMed
  42. Fu Y, et al. 2020. Mol Ther. 1214:28. PubMed
  43. Sun CC, et al. 2020. Genome Med. 0.553472222. PubMed
  44. Schmidleithner L et al. 2019. Immunity. 50(5):1232-1248 . PubMed
  45. Diao L, et al. 2022. iScience. 25:105511. PubMed
  46. Bangs DJ, et al. 2022. Cell Rep. 38:110266. PubMed
  47. Huang Y, et al. 2021. Radiother Oncol. 162:34. PubMed
  48. Zhao J, et al. 2022. J Nanobiotechnology. 20:62. PubMed
  49. Ren J, et al. 2021. Theranostics. 11:304. PubMed
  50. Tan X, et al. 2021. Front Oncol. 11:768222. PubMed
  51. Oliva Chávez AS, et al. 2021. Nat Commun. 12:3696. PubMed
  52. Liu Q, et al. 2021. Cell Death Dis. 12:240. PubMed
  53. Starkl P, et al. 2020. Immunity. 53(4):793-804.e9. PubMed
  54. Antonia O Cuff et al. 2017. Wellcome open research. 2:39 . PubMed
  55. Davis FM, et al. 2019. Arterioscler Thromb Vasc Biol. 39:2353. PubMed
  56. Pham THM, et al. 2020. Cell Host & Microbe. 27(1):54-67.e5.. PubMed
  57. Lesmeister M, et al. 2005. Reprod Biol Endocrinol. 29:74. PubMed
  58. Dolgova EV, et al. 2022. Int J Mol Sci. 23:. PubMed
  59. Mostafavi H, et al. 2022. PLoS Pathog. 18:e1010185. PubMed
  60. Sala D, et al. 2022. Mol Ther Methods Clin Dev. 25:170. PubMed
  61. Yu AI, et al. 2020. Cell Rep. 107471:31. PubMed
  62. Jiang S, et al. 2020. Scand J Immunol. e12867:91. PubMed
  63. Perner C, et al. 2020. Immunity. 53(5):1063-1077.e7. PubMed
  64. White C, et al. 2014. J Immunol. 193:5933. PubMed
  65. Chen Y, et al. 2012. PLoS One. 7:e47190. PubMed
  66. Ning X, et al. 2019. Mol Cell. 74:19. PubMed
  67. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  68. Deng P, et al. 2022. Cells. 11:. PubMed
  69. Li Y, et al. 2022. Clin Transl Immunology. 11:e1362. PubMed
  70. Zhan Y, et al. 2021. JCI Insight. 6:. PubMed
  71. Lee M, et al. 2014. PLoS One. 9:112666. PubMed
  72. Mingozzi F, et al. 2016. EMBO Mol Med. 8: 1039 - 1051. PubMed
  73. Solanki A, et al. 2018. Development. 145. PubMed
  74. Shields BD, et al. 2019. Cancer Res. 79:1113. PubMed
  75. Dang Y, et al. 2022. Cancer Cell Int. 22:88. PubMed
  76. Almeida AS, et al. 2021. Bio Protoc. 11:e4012. PubMed
  77. Geng T, et al. 2022. Methods Mol Biol. 2585:71. PubMed
  78. Park HB, et al. 2020. Oncoimmunology. 9:1772663. PubMed
  79. Kimball AS et al. 2019. Immunity. 51(2):258-271 . PubMed
  80. Naing A et al. 2019. Cell reports. 26(5):1242-1257 . PubMed
  81. Yang S, et al. 2019. Nat Commun. 10:2782. PubMed
  82. Carr RM, et al. 2021. Nat Commun. 12:2901. PubMed
  83. Pervaiz N, et al. 2021. Pigment Cell Melanoma Res. 34:918. PubMed
  84. Sun Y, et al. 2022. Nat Commun. 13:3916. PubMed
  85. Zhang B, et al. 2021. Nat Biomed Eng. 5:1288. PubMed
  86. Chen Q, et al. 2016. Nat Commun. 7:13193. PubMed
  87. Bogie JF, et al. 2020. Ther Adv Chronic Dis. 11:2040622320947378. PubMed
  88. Li Y, et al. 2020. Cell Stem Cell. 27(5):732-747.e7. PubMed
  89. Omori S, et al. 2021. Cell Reports. 34(6):108734. PubMed
  90. Wang X, et al. 2018. Mol Med Rep. 17:1660. PubMed
  91. Lee JS et al. 2018. Cell. 174(6):1559-1570 . PubMed
  92. Comazzetto S et al. 2018. Cell stem cell. 24(3):477-486 . PubMed
  93. Littwitz-Salomon E, et al. 2021. Nat Commun. 12:5376. PubMed
  94. Hanasoge Somasundara AV, et al. 2021. Cell Rep. 37:110099. PubMed
  95. Shi R, et al. 2022. Theranostics. 12:875. PubMed
  96. Jie X, et al. 2022. J Immunother Cancer. 10:. PubMed
  97. Harb H, et al. 2021. Immunity. 54(6):1186-1199.e7. PubMed
  98. Tacconi C, et al. 2021. Cell Reports. 35(2):108993. PubMed
  99. Elahi S, et al. 2020. Stem Cell Res. 43:101710. PubMed
  100. Akhter N, et al. 2016. J Biol Chem. 291: 23672 - 23680. PubMed
  101. Huang B, et al. 2015. PLoS One. 10: 0134715. PubMed
  102. Markey K, et al. 2014. J Immunol. 192:5426. PubMed
  103. Sreekumar PG, et al. 2018. J Control Release. 283:94. PubMed
  104. Garo LP, et al. 2019. Cell Rep. 28:3353. PubMed
  105. Li W, et al. 2019. Nat Commun. 10:3349. PubMed
  106. Xu X, et al. 2018. Cell. 175:1336. PubMed
  107. Reismann D, et al. 2017. Nat Commun.. 10.1038/s41467-017-01538-9. PubMed
  108. Ishidome T et al. 2017. EBioMedicine. 22:89-99 . PubMed
  109. Ding Y, et al. 2022. Cell Death Dis. 13:996. PubMed
  110. Tang X, et al. 2022. Cell Rep. 41:111673. PubMed
  111. Wei W, et al. 2022. mSystems. 7:e0046922. PubMed
  112. Zhao X, et al. 2022. Nat Protoc. 17:2240. PubMed
  113. Zhou H, et al. 2022. Oncoimmunology. 11:2057892. PubMed
  114. Yang J, et al. 2022. Microbiome. 10:149. PubMed
  115. Harnett MM, et al. 2022. Front Immunol. 13:953053. PubMed
  116. Koren E, et al. 2022. Nat Commun. 13:4628. PubMed
  117. Chen X, et al. 2021. Cell Rep. 37:109991. PubMed
  118. Ye P, et al. 2022. Front Cardiovasc Med. 8:810477. PubMed
  119. Zuo S, et al. 2021. J Immunother Cancer. 9:. PubMed
  120. Reinfeld BI, et al. 2021. Nature. 593:282. PubMed
  121. Du J, et al. 2012. Stem Cells. 30:1447. PubMed
  122. Weinheimer-Haus E, et al. 2014. PLoS One. 9:91355. PubMed
  123. Zheng L, et al. 2020. Front Oncol. 10:531131. PubMed
  124. Kruta M, et al. 2021. Cell Stem Cell. :. PubMed
  125. Moon HG et al. 2018. Immunity. 49(2):275-287 . PubMed
  126. Ren W, et al. 2018. Mucosal Immunol. 12:531. PubMed
  127. Liu W, et al. 2021. Cell Death Discov. 7:136. PubMed
  128. França TT, et al. 2021. JCI Insight. 6:. PubMed
  129. Carbone C, et al. 2021. J Immunother Cancer. 9:. PubMed
  130. Shannon JP, et al. 2021. STAR Protoc. 2:100790. PubMed
  131. Sun C, et al. 2022. J Adv Res. 35:71. PubMed
  132. Alsina-Sanchis E, et al. 2020. Mol Cancer Res. . PubMed
  133. Shannon JP, et al. 2021. Immunity. 54(2):276-290.e5. PubMed
  134. Choi EW, et al. 2020. Sci Rep. 10:12001. PubMed
  135. Yu X, et al. 2019. Nat Commun. 10:574. PubMed
  136. Cohen M et al. 2018. Cell. 175(4):1031-1044 . PubMed
  137. Ma W, et al. 2017. Cell Death & Disease. 10.1038/cddis.2017.47. PubMed
  138. Yang Z, et al. 2021. Onco Targets Ther. 14:4239. PubMed
  139. Puigdelloses M, et al. 2021. J Immunother Cancer. 9:. PubMed
  140. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  141. Port JR, et al. 2020. J Virol. 94:. PubMed
  142. Rashid MH, et al. 2021. Oncol Rep. 45:1171. PubMed
  143. Li Y, et al. 2021. Cell Death Dis. 12:1001. PubMed
  144. Zhang W, et al. 2019. Mar Drugs. 0.845138889. PubMed
  145. Nowlan B, et al. 2019. Haematologica. 105:71. PubMed
  146. Zhang W, et al. 2020. Nat Commun. 11:1187. PubMed
  147. Yu H, et al. 2021. Front Oncol. 11:736882. PubMed
  148. Xiao Y, et al. 2022. Nat Commun. 13:758. PubMed
  149. Zhang R, et al. 2022. Front Pharmacol. 13:870848. PubMed
  150. Ali S, et al. 2021. PLoS One. 16:e0246646. PubMed
  151. Yang Z, et al. 2021. Nat Commun. 12:4852. PubMed
  152. Wang Z, et al. 2021. Acta Pharm Sin B. 694:11. PubMed
  153. Chen R, et al. 2021. Cell Reports. 34(7):108751. PubMed
  154. Wu L, et al. 2020. Cell Rep. 33:108327. PubMed
  155. Zan H, et al. 2017. Nat Commun. 8:14244. PubMed
  156. Cabrera-Perez J, et al. 2016. J Immunol. 197: 1692 - 1698. PubMed
  157. Kang J, Lee J, Chang J 2016. PLoS One. 11: 0157015. PubMed
  158. Cabrera-Perez C, et al. 2015. J Immunol . 194:1609-20. PubMed
  159. He J, et al. 2020. Evid Based Complement Alternat Med. 2020:5637507. PubMed
  160. Roy S, et al. 2019. Front Immunol. 2.404166667. PubMed
  161. Scally S, et al. 2017. Nat Commun. . 10.1038/s41467-017-01924-3. PubMed
  162. Yi H, et al. 2021. Front Immunol. 12:719189. PubMed
  163. Qi J, et al. 2021. Nat Commun. 12:4755. PubMed
  164. Bent EH, et al. 2021. Nat Commun. 12:6218. PubMed
  165. Zhang YN, et al. 2021. Sci Adv. 7:eabj3107. PubMed
  166. Murdock BJ, et al. 2021. JCI Insight. 6:. PubMed
  167. Robertson TF, et al. 2021. J Cell Biol. 220:. PubMed
  168. Mohammadi MR, et al. 2021. Commun Biol. 4:685. PubMed
  169. Li X, et al. 2021. Cell Death Dis. 12:314. PubMed
  170. Chen X, et al. 2019. Med Sci Monit. 25:5389. PubMed
  171. Zhang X, et al. 2021. Nat Commun. 12:4536. PubMed
  172. Smith-Díaz CC, et al. 2021. Front Oncol. 11:709543. PubMed
  173. Tsai HI, et al. 2021. EMBO Mol Med. 13:e12834. PubMed
  174. Wang J, et al. 2022. Clin Transl Med. 12:e718. PubMed
  175. Lai Y, et al. 2022. Clin Transl Med. 12:e999. PubMed
  176. Zhang J, et al. 2022. Biomater Res. 26:44. PubMed
  177. Li M, et al. 2021. Br J Pharmacol. 178:2617. PubMed
  178. Yang YS, et al. 2022. Nat Commun. 13:6175. PubMed
  179. Harb H, et al. 2020. Nat Immunol. 1359:21. PubMed
  180. Campolo M, et al. 2020. Int J Mol Sci. 21:00. PubMed
  181. Baumann D, et al. 2020. Nat Commun. 1.969444444. PubMed
  182. Chen C, et al. 2020. Front Cell Neurosci. 14:8. PubMed
  183. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
  184. Chen Y, et al. 2022. Nat Commun. 13:4468. PubMed
  185. Nam J, et al. 2021. Adv Ther (Weinh). 4:. PubMed
  186. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  187. Zhou H, et al. 2021. Cell Death Discov. 7:332. PubMed
  188. Yang Z, et al. 2021. Nat Commun. 12:4299. PubMed
  189. van den Berk P, et al. 2020. Cell Rep. 33:108533. PubMed
  190. Xu Y, et al. 2016. Nat Commun. 7:12073. PubMed
  191. Zheng DW, et al. 2020. Nat Commun. 3.865972222. PubMed
  192. Jia H, et al. 2018. Int J Oncol. 53:949. PubMed
  193. Chao Y, et al. 2020. Sci Adv. 6:eaaz4204. PubMed
  194. Jiang Y, et al. 2021. Nat Commun. 12:742. PubMed
  195. Magee JA, et al. 2021. Stem Cell Reports. 16:20. PubMed
  196. Fujimoto M, et al. 2022. Nat Commun. 13:5408. PubMed
  197. Cané S, et al. 2021. J Immunother Cancer. 9:. PubMed
  198. Ravindran Menon D, et al. 2021. Pharmaceuticals (Basel). 14:. PubMed
  199. Le QV, et al. 2022. Bioact Mater. 15:160. PubMed
  200. Aulova KS, et al. 2022. Molecules. 27:. PubMed
  201. Yang N, et al. 2022. Nat Commun. 13:2336. PubMed
  202. Guo X, et al. 2020. J Cell Mol Med. . PubMed
  203. Simoni L, et al. 2020. Cell Rep. 33:108330. PubMed
  204. Yu H, et al. 2015. PLoS One. 10: 0143001. PubMed
  205. Pan X, et al. 2019. BMC Complement Altern Med. 19:163. PubMed
  206. Li K, et al. 2020. Nat Commun. 0.795138889. PubMed
  207. Hidalgo San Jose L, et al. 2020. Cell Rep. 30:69. PubMed
  208. Zukauskas A, et al. 2018. mSphere. 3:e00303. PubMed
  209. Tao Z, et al. 2022. Cells. 11:. PubMed
  210. Tang T, et al. 2022. J Immunother Cancer. 10:. PubMed
  211. Zhou Y, et al. 2022. Theranostics. 12:5488. PubMed
  212. Chen LH, et al. 2021. Sci Rep. 11:19478. PubMed
  213. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  214. Wang J, et al. 2021. Am J Cancer Res. 11:2005. PubMed
  215. Wang F, et al. 2021. Neoplasia. 23:281. PubMed
  216. Roberto MP, et al. 2021. Immunity. 54(8):1807-1824.e14. PubMed
  217. Goldberg EL, et al. 2021. Cell Metabolism. :. PubMed
  218. Tanegashima K et al. 2017. EBioMedicine. 24:247-256 . PubMed
  219. Crowe J, et al. 2020. PLoS Pathog. 16:e1008391. PubMed
  220. Tur J, et al. 2020. Cell Reports. 32(8):108079. PubMed
  221. Mincham KT, et al. 2021. Front Immunol. 11:601494. PubMed
  222. Zheng Y, et al. 2022. Transl Res. :. PubMed
  223. Gawish R, et al. 2022. Elife. 11:. PubMed
  224. Li J, et al. 2022. Nat Commun. 13:1481. PubMed
  225. Li J, et al. 2021. eLife. 10:00. PubMed
  226. Trivedi S, et al. 2020. Elife. 9:00. PubMed
  227. Tripathi D, et al. 2016. Nat Commun. 7:13896. PubMed
  228. Fan X, et al. 2014. PLoS One. 9:107638. PubMed
  229. Martínez-Vicente P, et al. 2019. PLoS Pathog. 15:e1007658. PubMed
  230. Liu WL, et al. 2019. Nat Commun. 10:3199. PubMed
  231. Kubli SP, et al. 2019. Nat Commun. 10:2678. PubMed
  232. Sun Q, et al. 2022. J Inflamm Res. 15:5827. PubMed
  233. Cao Y, et al. 2022. Small. 18:e2203466. PubMed
  234. Li C, et al. 2022. Front Cell Dev Biol. 10:913824. PubMed
  235. Xu Z, et al. 2022. Cell Death Dis. 13:502. PubMed
  236. Erens C, et al. 2022. Biomedicines. 10:. PubMed
  237. Zhang J, et al. 2021. Stem Cell Res Ther. 12:579. PubMed
  238. Gu Z, et al. 2021. Nat Genet. 53:672. PubMed
  239. Zuo S, et al. 2021. EBioMedicine. 64:103240. PubMed
  240. Zheng QY, et al. 2020. FASEB J. 34:10590. PubMed
RRID
AB_312660 (BioLegend Cat. No. 100203)
AB_312661 (BioLegend Cat. No. 100204)

Antigen Details

Structure
Ig superfamily, CD3/TCR, 20 kD
Distribution

Thymocytes (differentiation dependent), mature T cells, NK-T cells

Function
Antigen recognition, TCR signal transduction, T cell activation
Ligand/Receptor
Peptide antigen/MHC-complex
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Davis MM. 1990. Annu. Rev. Biochem. 59:475.
3. Weiss A, et al. 1994. Cell 76:263.

Gene ID
12502 View all products for this Gene ID
UniProt
View information about CD3 on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD3 Reagents Request Custom Conjugation
Description Clone Applications
FITC anti-mouse CD3 17A2 FC
PE anti-mouse CD3 17A2 FC
Purified anti-mouse CD3 17A2 FC, IHC-F, IP, ICC
Alexa Fluor® 647 anti-mouse CD3 17A2 FC, IHC-F, 3D IHC
Alexa Fluor® 488 anti-mouse CD3 17A2 FC, IHC-F, 3D IHC
Pacific Blue™ anti-mouse CD3 17A2 FC
Alexa Fluor® 700 anti-mouse CD3 17A2 FC
PerCP/Cyanine5.5 anti-mouse CD3 17A2 FC
PE/Cyanine7 anti-mouse CD3 17A2 FC
APC/Cyanine7 anti-mouse CD3 17A2 FC
Brilliant Violet 421™ anti-mouse CD3 17A2 FC, ICC
Brilliant Violet 570™ anti-mouse CD3 17A2 FC
Brilliant Violet 650™ anti-mouse CD3 17A2 FC
Brilliant Violet 785™ anti-mouse CD3 17A2 FC
Brilliant Violet 510™ anti-mouse CD3 17A2 FC
APC anti-mouse CD3 17A2 FC
Ultra-LEAF™ Purified anti-mouse CD3 17A2 FC, IHC-F, IP, ICC
Brilliant Violet 605™ anti-mouse CD3 17A2 FC
Alexa Fluor® 594 anti-mouse CD3 17A2 IHC-F, FC, 3D IHC, SB
Brilliant Violet 711™ anti-mouse CD3 17A2 FC
Biotin anti-mouse CD3 17A2 FC, IHC-F
PE/Dazzle™ 594 anti-mouse CD3 17A2 FC
APC/Fire™ 750 anti-mouse CD3 17A2 FC
Brilliant Violet 750™ anti-mouse CD3 17A2 FC
TotalSeq™-A0182 anti-mouse CD3 17A2 PG
TotalSeq™-B0182 anti-mouse CD3 17A2 PG
Spark Blue™ 550 anti-mouse CD3 17A2 FC
Spark NIR™ 685 anti-mouse CD3 17A2 FC
TotalSeq™-C0182 anti-mouse CD3 17A2 PG
APC/Fire™ 810 anti-mouse CD3 17A2 FC
PE/Fire™ 640 anti-mouse CD3 17A2 FC
Spark YG™ 570 anti-mouse CD3 17A2 IHC-F
PE/Fire™ 700 anti-mouse CD3 17A2 FC
PE/Cyanine5 anti-mouse CD3 17A2 FC
Spark Blue™ 574 anti-mouse CD3 Antibody 17A2 FC
Spark Violet™ 423 anti-mouse CD3 17A2 FC
PE/Fire™ 810 anti-mouse CD3 17A2 FC
Spark Red™ 718 anti-mouse CD3 17A2 FC
Go To Top Version: 1    Revision Date: 11/30/2012

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

 

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

 

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

  • FITC anti-mouse CD3

  • PE anti-mouse CD3

  • Purified anti-mouse CD3

  • Alexa Fluor® 647 anti-mouse CD3

  • Alexa Fluor® 488 anti-mouse CD3

  • Pacific Blue™ anti-mouse CD3

  • Alexa Fluor® 700 anti-mouse CD3

  • PerCP/Cyanine5.5 anti-mouse CD3

  • PE/Cyanine7 anti-mouse CD3

  • APC/Cyanine7 anti-mouse CD3

  • Brilliant Violet 421™ anti-mouse CD3

  • Brilliant Violet 570™ anti-mouse CD3

  • Brilliant Violet 650™ anti-mouse CD3

  • Brilliant Violet 785™ anti-mouse CD3

  • Brilliant Violet 510™ anti-mouse CD3

  • APC anti-mouse CD3

  • Ultra-LEAF™ Purified anti-mouse CD3

  • Brilliant Violet 605™ anti-mouse CD3

  • Alexa Fluor® 594 anti-mouse CD3

  • Brilliant Violet 711™ anti-mouse CD3

  • Biotin anti-mouse CD3

  • PE/Dazzle™ 594 anti-mouse CD3

  • APC/Fire™ 750 anti-mouse CD3

  • Brilliant Violet 750™ anti-mouse CD3

  • TotalSeq™-A0182 anti-mouse CD3

  • TotalSeq™-B0182 anti-mouse CD3

  • Spark Blue™ 550 anti-mouse CD3

  • Spark NIR™ 685 anti-mouse CD3

  • TotalSeq™-C0182 anti-mouse CD3

  • APC/Fire™ 810 anti-mouse CD3

  • PE/Fire™ 640 anti-mouse CD3

  • Spark YG™ 570 anti-mouse CD3

  • PE/Fire™ 700 anti-mouse CD3

  • PE/Cyanine5 anti-mouse CD3

  • Spark Blue™ 574 anti-mouse CD3 Antibody

  • Spark Violet™ 423 anti-mouse CD3

  • PE/Fire™ 810 anti-mouse CD3

  • Spark Red™ 718 anti-mouse CD3

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account